Wall Street analysts expect that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will announce ($0.91) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.74) and the lowest estimate coming in at ($1.06). Rhythm Pharmaceuticals posted earnings of ($0.74) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 23%. The firm is scheduled to report its next quarterly earnings report on Friday, March 13th.
According to Zacks, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.19) to ($3.82). For the next fiscal year, analysts expect that the company will post earnings of ($3.38) per share, with EPS estimates ranging from ($4.05) to ($3.06). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Friday, November 1st. The company reported ($1.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.06) by $0.02.
In other Rhythm Pharmaceuticals news, Director Todd Foley sold 102,682 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.78, for a total value of $2,236,413.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 418,709 shares of company stock worth $9,376,707. Insiders own 4.45% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in shares of Rhythm Pharmaceuticals in the third quarter valued at approximately $1,547,000. DekaBank Deutsche Girozentrale bought a new position in Rhythm Pharmaceuticals in the 2nd quarter valued at $564,000. Susquehanna International Group LLP acquired a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter valued at $328,000. Rice Hall James & Associates LLC boosted its holdings in Rhythm Pharmaceuticals by 172.5% in the second quarter. Rice Hall James & Associates LLC now owns 63,217 shares of the company’s stock valued at $1,391,000 after acquiring an additional 40,015 shares during the last quarter. Finally, Fosun International Ltd raised its holdings in Rhythm Pharmaceuticals by 37.0% during the 2nd quarter. Fosun International Ltd now owns 40,720 shares of the company’s stock worth $883,000 after purchasing an additional 11,000 shares during the last quarter. Institutional investors own 78.13% of the company’s stock.
Shares of NASDAQ:RYTM opened at $22.01 on Friday. The company has a 50 day moving average of $21.83 and a 200-day moving average of $22.15. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.02. Rhythm Pharmaceuticals has a twelve month low of $18.00 and a twelve month high of $31.94.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.